Genprex, Inc. (GNPX)
NASDAQ: GNPX · IEX Real-Time Price · USD
2.710
-0.030 (-1.09%)
At close: Mar 27, 2024, 4:00 PM
2.610
-0.100 (-3.69%)
After-hours: Mar 27, 2024, 7:47 PM EDT
Company Description
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes.
Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer.
The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.
Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Genprex, Inc.
Country | United States |
Founded | 2009 |
IPO Date | Mar 29, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 31 |
CEO | John Rodney Varner |
Contact Details
Address: 1601 Trinity Street, Bldg. B, Suite 3.322 Austin, Texas 78712 United States | |
Phone | 512-537-7997 |
Website | genprex.com |
Stock Details
Ticker Symbol | GNPX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001595248 |
CUSIP Number | 372446104 |
ISIN Number | US3724462037 |
Employer ID | 90-0772347 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
John Rodney Varner | Co-Founder, Chairman, President and Chief Executive Officer |
Ryan M. Confer M.S. | Chief Financial Officer |
David M. Schloss | Senior Vice President of Human Resources |
Thomas C. Gallagher Esq. | Senior Vice President of Intellectual Property and Licensing |
Dr. Mark S. Berger M.D. | Chief Medical Officer |
Dr. Suzanne Thornton-Jones | Senior Vice President of Regulatory Affairs and Quality |
Dr. Jack A. Roth F.A.C.S., M.D. | Chairman of Scientific and Medical Advisory Board |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 20, 2024 | 424B5 | Filing |
Mar 20, 2024 | 8-K | Current Report |
Mar 6, 2024 | 8-K | Current Report |
Feb 26, 2024 | 8-K | Current Report |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 5, 2024 | 8-K | Current Report |
Feb 2, 2024 | 8-K | Current Report |
Jan 31, 2024 | 8-K | Current Report |
Jan 5, 2024 | 8-K | Current Report |
Dec 18, 2023 | 8-K | Current Report |